Royalty Pharma Q1 Portfolio Receipts +10% to $925M; raises FY 2026 guidance

Royalty Pharma plc

2026-Q1 EPS reported $0.67 revenue$630,576,000

Royalty Receipts grew 13% to $887M; driven by Tremfya (+79%), Voranigo (+140%), Evrysdi (+51%).
Adjusted EBITDA non-GAAP $889M (+21% YoY); Portfolio Cash Flow $722M (+18%).
Full-year 2026 Portfolio Receipts guidance raised to $3,325M-$3,450M (prev. $3,275M-$3,425M).
Announced up to $1.25B in royalty transactions; $528M capital deployed in Q1.
Recorded $69M non-cash impairment on Tazverik; positive Phase 3 data for daraxonrasib and Myqorzo.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Royalty Pharma plc reported first quarter of 2026 results: revenue $925 million. Guidance raised.

Period: first quarter of 2026
Revenue: $925 million
Guidance: raised
Result: reported results

Exact text from the filing

Press Release May 6, 2026 R oyalty Pharma reports first quarter 2026 results Portfolio Rece ipts growth o f 10% to $925 million ; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million

View on SEC.gov

Browse all earnings releases →

Royalty Pharma plc filing history →

Source: SEC EDGAR

accession 0001802768-26-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.